Drug Search Results
More Filters [+]

ROCK-425

Alternative Names: ROCK-425, ROCK425, ROCK 425
Latest Update: 2024-05-10
Latest Update Note: Clinical Trial Update

Product Description

Rock425 (CCR4-IL2 IT) is genetically engineered to contain both anti-human CCR4 scFv and human IL2 fused to truncated diphtheria toxin. It is expressed using a proprietary diphtheria toxin-resistant P. pastoris yeast expression system. (Sourced from: https://rockimmune.com/#:~:text=Leading%20Drug%20Candidate,-Rock425%20(CCR4%2DIL2&text=Show%20More-,Rock425%20(CCR4%2DIL2%20IT)%20is%20genetically%20engineered%20to%20contain,pastoris%20yeast%20expression%20system.)

Mechanisms of Action: CCR4 Inhibitor,IL2 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Rock Immune
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ROCK-425

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: T-Cell Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title